A renowned medical center in Manhattan has ceased its transgender treatment program for children, a decision framed not as a moral stance, but as a response to a rapidly shifting legal landscape. The closure of NYU Langone’s program signals a dramatic turn in the availability of these services, driven by recent federal actions.
The change follows a January executive order issued by the President, titled “Protecting Children from Chemical and Surgical Mutilation.” This order restricts access to what it terms ‘gender-affirming care’ for individuals under the age of nineteen, impacting a wide range of healthcare provisions.
The executive order’s reach extends to federally-funded insurance programs like TRICARE and Medicaid, potentially denying coverage for these treatments to millions. Critically, it also threatens to revoke federal funding from medical schools and hospitals that continue to offer gender transition services to minors.
The order’s language is stark, declaring a national policy against funding or supporting the “transition” of a child, and promising rigorous enforcement of laws prohibiting such procedures. It characterizes the trend as a “stain” on the nation’s history, demanding its cessation.
NYU Langone cited both the departure of its medical director and the evolving “regulatory environment” as factors in its decision. While the program is discontinued, the institution maintains its commitment to managing the transition of care for existing patients and will continue offering pediatric mental health services.
The Department of Justice has escalated the pressure, issuing over twenty subpoenas to doctors and clinics suspected of providing gender-affirming care to minors. These investigations delve into potential healthcare fraud, false statements, and even the reclassification of gender medicine as a form of female genital mutilation.
This legal offensive stems from a directive issued by the Attorney General, alleging that “gender ideology” has permeated American culture and medicine. The directive claims children are undergoing irreversible procedures based on flawed science and the influence of activist groups.
The Attorney General’s memo explicitly states the DOJ will pursue gender-affirming surgeries on minors as potential violations of existing laws prohibiting female genital mutilation, carrying penalties of up to ten years in prison per offense. Investigations will also target pharmaceutical companies and doctors regarding the prescribing of puberty blockers and hormones.
NYU Langone is not alone in this shift. Other institutions, including the University of Michigan hospital system and Baystate Health in Massachusetts, have also suspended or ended similar programs, reflecting the growing legal and political scrutiny.
This unfolding situation arrives alongside a landmark legal victory for Fox Varian, a young woman who underwent a double mastectomy as a minor after being encouraged by medical professionals. Varian was awarded $2 million in damages after successfully arguing a malpractice claim.
Varian’s case marks the first instance of a detransitioner winning a malpractice lawsuit at trial, establishing a precedent that could significantly alter the landscape of gender-affirming care and raise questions about the informed consent process for minors.
